Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
- Gross Profit Margin
- The gross profit margin displayed a generally upward trend from 65.58% in early 2020 to peaks around 69.2% by the end of 2023. Thereafter, it showed slight fluctuations but remained stable near 68% through mid-2025. This indicates an overall improvement in the company’s core profitability relative to revenue over the analyzed period.
- Operating Profit Margin
- The operating profit margin followed a positive trajectory from 23.6% in early 2020, reaching a peak of approximately 25.61% by late 2023. Although minor dips and recoveries occurred, the margin remained fairly consistent above 23% through 2025. This trend suggests enhanced operational efficiency or cost management during the timeline, sustaining healthy operating profitability.
- Net Profit Margin
- The net profit margin exhibited notable volatility, starting near 17.8% in 2020, rising sharply to 22.26% by mid-2021, then fluctuating with a significant spike to above 40% during late 2023 to early 2024. Following this peak, the margin fell back to near 15%-27% in 2025. This variability may reflect non-operating factors, such as extraordinary items, tax impacts, or one-time gains influencing net profitability.
- Return on Equity (ROE)
- The ROE showed a strong upward trend from approximately 23% in early 2020, peaking at over 54% in early 2024. Subsequently, it declined yet remained elevated relative to initial levels, around 28% by mid-2025. This indicates substantial improvements in equity returns over the period, potentially driven by effective capital management and profitability enhancements.
- Return on Assets (ROA)
- The ROA mirrored the improvement seen in ROE, rising from 8.41% in early 2020 to a high near 22% in late 2023 and early 2024. As with ROE, it declined afterward but stabilized above 11% by mid-2025. This pattern suggests increased efficiency in asset utilization contributing positively to overall returns.
Return on Sales
Return on Investment
Gross Profit Margin
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||||
| Sales to customers | ||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
1 Q3 2025 Calculation
Gross profit margin = 100
× (Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024)
÷ (Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025
+ Sales to customersQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Sales to Customers
- The sales figures demonstrate a cyclical pattern with notable fluctuations. The quarterly sales peaked at $24,804 million in December 2020, followed by a decline reaching a low of $20,894 million in April 2023. Subsequently, the sales gradually increased again, attaining approximately $23,993 million by September 2025. This indicates oscillating demand or seasonal effects over the observed periods, with an overall trend reflecting periods of growth interrupted by declines.
- Gross Profit
- Gross profit values exhibit a somewhat correlated pattern to sales but with less volatility. Peak gross profit occurred at $16,849 million in December 2020. After declining through 2022 and early 2023, gross profit values ranged between approximately $14,200 million and $16,690 million later in the timeline, suggesting improvements in profitability or cost control despite fluctuating sales. The gross profit trend seems to partially recover toward the end of the data horizon.
- Gross Profit Margin
- The gross profit margin shows a consistent upward trend, starting at around 65.58% in April 2021 and increasing steadily to exceed 69% by late 2024, with minor fluctuations around that level thereafter. This improvement in margin implies enhanced operational efficiency, better pricing power, or a favorable product mix contributing to higher profitability relative to sales revenue.
- Overall Analysis
- The data indicates that while sales volumes experienced ups and downs, the company has improved its gross profit margins over time, suggesting an emphasis on cost management or strategic pricing. The rising margin despite periodic declines in sales hints at greater margin stability and possibly more effective control of production and operational costs. The gross profit's moderate variation relative to sales fluctuations supports this interpretation, reflecting improved financial resilience.
Operating Profit Margin
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Operating earnings | ||||||||||||||||||||||||||||||
| Sales to customers | ||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
1 Q3 2025 Calculation
Operating profit margin = 100
× (Operating earningsQ3 2025
+ Operating earningsQ2 2025
+ Operating earningsQ1 2025
+ Operating earningsQ4 2024)
÷ (Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025
+ Sales to customersQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Earnings
- The operating earnings demonstrate considerable volatility over the periods analyzed. Starting from a high point near 5,788 million US dollars in early 2020, there is a notable dip in the second quarter of 2020, reaching 3,990 million US dollars. Following this trough, operating earnings generally trend upward, peaking around 6,595 million US dollars by April 2021. The following quarters show fluctuations with peaks and troughs but maintain a range mostly between approximately 4,000 and 6,500 million US dollars. Toward the end of the timeline, operating earnings experience a downward dip again in the middle of 2024, but recover and reach a high of roughly 7,033 million US dollars by late 2025.
- Sales to Customers
- Sales figures reveal a relatively more stable but slowly increasing trend. Sales begin in the range of about 20,691 million US dollars in early 2020, followed by a slight decline in the second quarter to 18,336 million US dollars. After this drop, sales recover and progressively increase over time, reaching near 23,993 million US dollars by the last quarter observed in 2025. The sales data show minor short-term fluctuations but maintain an overall upward trajectory, indicating steady revenue growth from customers.
- Operating Profit Margin
- Operating profit margin data is incomplete for early 2020; however, starting from late 2020, it consistently remains within a narrow range of approximately 23% to 25.5%. This suggests that despite variations in operating earnings and sales values, the company has maintained a relatively stable profitability ratio. Slight increases and decreases within this margin range over the quarters indicate efficient management of costs relative to sales.
- Overall Trends and Insights
- The data illustrates an overall recovery and growth phase after an initial downturn in early 2020, likely influenced by external factors impacting operating earnings and sales. Sales to customers demonstrate resilience and consistent growth, which supports operating earnings stability. The stable operating profit margins in the 23%-25% range signify effective cost control and profitability maintenance across varying economic conditions. Periodic dips in both operating earnings and sales suggest exposure to short-term challenges, yet the trend toward the end of the period is positive with increases in both sales and operating earnings.
Net Profit Margin
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net earnings (loss) | ||||||||||||||||||||||||||||||
| Sales to customers | ||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
1 Q3 2025 Calculation
Net profit margin = 100
× (Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025
+ Net earnings (loss)Q4 2024)
÷ (Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025
+ Sales to customersQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals notable fluctuations over the examined quarters in several key performance indicators including net earnings, sales to customers, and net profit margin. These metrics provide a comprehensive overview of operational efficiency, profitability, and revenue trends.
- Net Earnings (Loss)
- Net earnings demonstrate significant variability, with values oscillating between positive and negative outcomes. The figures start relatively strong, then decrease sharply in late 2020, followed by recovery and sporadic peaks and troughs. Notably, a substantial surge occurred in the quarter ending October 2023, reaching 26028 million US dollars, which starkly contrasts with a significant drop to -68 million US dollars shortly before. This suggests episodic impacts possibly due to extraordinary items or shifts in business conditions. The earnings trend in the most recent quarters shows moderate stabilization but with a wide range in magnitude.
- Sales to Customers
- Sales values remain relatively stable across the periods, hovering mostly within the range of approximately 20,000 to 24,000 million US dollars. There is a slight upward trajectory over the long term, indicating steady demand and consistent revenue generation. Minor fluctuations appear quarterly but do not suggest any dramatic shifts or seasonal extremes. The latest quarters see a continuation of this stable revenue pattern with a slight increase trending toward 24,000 million US dollars.
- Net Profit Margin
- The net profit margin, expressed as a percentage, exhibits an overall increasing trend with pronounced volatility. Initial data points are missing, but from early 2021 onward, margins rise from approximately 17-20% to peaks exceeding 40% in late 2023 and early 2024, indicative of improved profitability during those quarters. However, the margin subsequently drops sharply, falling back to the 15-25% range in later periods. This fluctuation may reflect varying cost structures, pricing power, or exceptional items affecting profitability aside from revenue changes. The high margins in late 2023 correspond with the spike in net earnings, reinforcing the interpretation of extraordinary events impacting those quarters.
In summary, while sales remain stable and reflect consistent market demand, both net earnings and profit margins are subject to significant volatility. This lack of consistency in profitability measures could point to episodic impacts, possible restructuring, or changing business conditions. The general upward trend in profitability during some periods suggests potential for strong earnings performance, but variability highlights the importance of careful monitoring and analysis of underlying factors influencing these financial metrics.
Return on Equity (ROE)
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net earnings (loss) | ||||||||||||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity | ||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
1 Q3 2025 Calculation
ROE = 100
× (Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025
+ Net earnings (loss)Q4 2024)
÷ Total Johnson & Johnson shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial data reveals notable fluctuations in net earnings, shareholders’ equity, and return on equity (ROE) over the observed periods.
- Net Earnings (Loss)
- Net earnings display considerable variation, with a notable high of 26,028 million US dollars recorded in October 2023, sharply contrasting earlier quarters where values typically ranged between approximately 1,700 million and 6,200 million US dollars. Several quarters exhibit a decline, most prominently December 2020 with 1,738 million US dollars and April 2023 showing a negative figure of -68 million US dollars, indicating a loss. From early 2024 onwards, net earnings appear somewhat stabilized but at moderate levels compared to the peak in late 2023, fluctuating between roughly 2,500 million and 11,000 million US dollars.
- Total Shareholders’ Equity
- The total shareholders’ equity shows a generally increasing trajectory, moving from approximately 61.3 billion US dollars in early 2020 to nearly 79.3 billion US dollars by late 2025. Despite some minor dips and periods of consolidation, the trend indicates sustained growth in shareholder value. For instance, slight decreases are observed in mid-2023 and early 2024 but are followed by resumed growth in subsequent quarters.
- Return on Equity (ROE)
- ROE presents a strong upward trend with high volatility. Early available data from April 2021 indicates ROE values in the low to mid-20s percentile, fluctuating marginally between about 17.4% and 28.2%. A marked increase is noted from October 2023 onward, where ROE spikes drastically to exceed 50%, peaking around 54.9% in September 2024. Following this peak, ROE moderates to the high 20s and low 30s percent toward late 2025. This sharp increase aligns with the extraordinary net earnings in late 2023, suggesting highly efficient utilization of equity in that period.
Overall, the financial indicators imply a period of significant earnings volatility, with equity steadily growing and ROE reflecting heightened profitability efficiency particularly in late 2023 and 2024. The negative earnings instance and subsequent recovery highlight potential operational or market challenges that were effectively managed to restore profitability. Equity growth supports a strong balance sheet foundation, while the elevated ROE during the latter periods indicates impressive returns relative to shareholder investment.
Return on Assets (ROA)
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net earnings (loss) | ||||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
1 Q3 2025 Calculation
ROA = 100
× (Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025
+ Net earnings (loss)Q4 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analyzed financial data reveals several notable trends and fluctuations over the presented periods. The net earnings demonstrate considerable variability, with initial strong performances followed by significant declines and occasional sharp recoveries. For example, there is a marked drop in net earnings during the final quarter of 2022, reaching a negative level, followed by a substantial rebound in subsequent quarters, including a peak quarter in late 2023 where earnings surged dramatically. This pattern suggests periods of volatility possibly linked to operational or market factors affecting profitability.
Total assets show a generally increasing trend throughout the timeline, with some periods of stabilization and minor declines. The asset base expands significantly in mid-2022 and again in the early quarters of 2023, before experiencing a notable decrease toward the end of 2023. Thereafter, the asset levels gradually rise again, indicating ongoing investment or growth activities despite occasional contractions. This trend implies an overall asset growth strategy with intermittent adjustments.
The Return on Assets (ROA) figures, though incomplete for the earliest periods, provide insights into efficiency and profitability relative to asset size. ROA maintains a strong positive performance from early 2021 onwards, peaking substantially in late 2023 and early 2024 with values exceeding 20%, which is indicative of highly efficient asset utilization during these quarters. However, there is a sharp decline in ROA following these peaks, followed by a gradual recovery that stabilizes slightly above 10% toward the latest observed periods. This fluctuation in ROA corresponds with the volatility in net earnings and suggests variations in operational effectiveness or market conditions across the quarters.
- Net Earnings
- Exhibited significant volatility with a notable plunge into negative territory in late 2022, followed by exceptional recovery and a peak in late 2023, then moderate fluctuations afterward.
- Total Assets
- Displayed an overall upward trend with periods of stabilization and occasional decreases, indicating expansion with some asset reallocation or divestitures.
- Return on Assets (ROA)
- Showed strong profitability starting 2021, peaking dramatically in late 2023 and early 2024, then declining and stabilizing around moderate levels, reflecting changing efficiency in asset usage.
In summary, the data reflects a pattern of cyclical performance with periods of strong growth and profitability interspersed with temporary setbacks. Asset growth remains consistent overall, supporting long-term operational capacity. The ROA trends suggest phases of enhanced operational efficiency that contribute materially to net earnings fluctuations. These dynamics could be indicative of external market influences or internal strategic shifts impacting financial outcomes across the analyzed timeframe.